Zonisamide

Introduction Overview

Generic Name

zonisamide

Brand Name

Zonegran, Zonisade

Dosage Form

oral capsule (100 mg, 50 mg, 25 mg), oral suspension (100 mg/5 mL)

Drug Class

Carbonic anhydrase inhibitor anticonvulsants

Pharmacokinetics

Absorption:
Zonisamide is well absorbed from the gastrointestinal tract following oral administration, with bioavailability approaching 100%. Peak plasma concentrations are typically reached within 2 to 6 hours post-dose. The absorption is unaffected by food intake, thus tablets or capsules can be administered with or without food, which enhances patient compliance. Its oral suspension form also ensures consistent absorption profiles similar to the capsule form, making it suitable for patients with swallowing difficulties. The drug's high oral bioavailability contributes to its effectiveness in seizure control.

Distribution:
Zonisamide exhibits a moderate volume of distribution, approximately 1.1 to 1.8 L/kg, suggesting distribution into both plasma and various tissues, including the brain, the target site of action. It is approximately 40% protein bound, primarily to albumin, which minimizes drug displacement interactions. The ability of zonisamide to cross the blood-brain barrier is critical for its anticonvulsant effects. Animal and clinical studies have demonstrated that it achieves therapeutic concentrations in the central nervous system. The moderate protein binding also means that changes in plasma protein levels due to illness may not profoundly affect free drug concentrations.

Metabolism:
Zonisamide is metabolized primarily in the liver via two main pathways. The predominant metabolic pathway involves reduction of the 1,2-benzisoxazole ring to form a major inactive metabolite, and the secondary pathway is through cytochrome P450 enzyme CYP3A4-mediated oxidation. The involvement of CYP3A4 has clinical implications due to potential drug-drug interactions with inducers or inhibitors of this enzyme, potentially altering zonisamide plasma levels. Metabolism is extensive, with minimal unchanged drug excreted via urine reflecting significant hepatic biotransformation. The drug's metabolic pathways allow for relatively predictable plasma levels but necessitate caution when used with other hepatically metabolized drugs.

Elimination:
Zonisamide and its metabolites are predominantly eliminated renally, with approximately 62% excreted in the urine predominantly as metabolites, and 3% as unchanged drug. The elimination half-life is notably long, ranging from 50 to 70 hours in healthy adults, which supports once or twice daily dosing schedules. The long half-life also means steady state concentrations are achieved slowly, often requiring up to two weeks. Renal function significantly affects the elimination of zonisamide, therefore, dose adjustments may be necessary in patients with renal impairment. Additionally, the long half-life necessitates careful monitoring during initiation and dosage changes to avoid accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
Zonisamide is available in the following oral dosage forms: capsules and oral suspension. The capsules come in strengths of 100 mg, 50 mg, and 25 mg, allowing flexible titration tailored to patient needs. The oral suspension is formulated as 100 mg per 5 mL, providing an easier administration route for patients with difficulties swallowing capsules or for pediatric use.

Dosages for Adults and Adolescents:
Zonisamide is indicated for adjunctive therapy of partial seizures in adults and adolescents aged 16 years and older. The recommended initial dose is 100 mg orally once daily. The dose can be titrated upwards in increments of 100 mg every 2 weeks based on clinical response and tolerability, progressing to 200 mg/day (either as a single dose or divided twice daily), and potentially increasing to 300 mg/day and 400 mg/day following similar titration steps. The maintenance dose is generally 400 mg/day, although doses up to a maximum of 600 mg/day have been used. Due to the drug’s long half-life, steady-state plasma concentrations are achieved only after approximately two weeks at a stable dose. Therefore, slower titration is advisable to minimize adverse effects. Doses above 300 mg/day have shown increased frequency of side effects and the marginal benefit beyond 100–200 mg/day is uncertain.

Specific Patient Populations:
Zonisamide is not recommended for use in pediatric patients under 16 years of age due to insufficient safety and efficacy data. Caution is advised in patients with renal impairment, as decreased renal clearance can lead to drug accumulation, necessitating dose adjustments and careful monitoring. Similarly, hepatic impairment may affect metabolism, requiring clinical judgment for dosing modifications. Pregnant women should use zonisamide only if the potential benefit justifies the risk to the fetus, and effective contraception is advised during and for at least one month following therapy cessation. Additionally, care is required when used in patients with sulfa allergy history, as zonisamide is a sulfonamide-derived anticonvulsant and can cause hypersensitivity reactions.

Mechanism Of Action

Zonisamide exerts its anticonvulsant effect primarily through multiple mechanisms at the neuronal level, contributing to its efficacy in treating partial seizures. It inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and preventing repetitive firing of action potentials, which are critical for seizure propagation. This action reduces neuronal excitability by suppressing rapid, repetitive neuronal firing.

Additionally, zonisamide blocks T-type calcium channels, which are involved in the burst firing of thalamic neurons implicated in seizure activity, especially absence seizures. The blockade of these channels helps attenuate abnormal thalamocortical rhythms that facilitate seizure generation.

Moreover, zonisamide acts as a weak carbonic anhydrase inhibitor. Inhibition of carbonic anhydrase leads to mild acidosis in the brain microenvironment, which is thought to contribute to seizure control by altering ionic gradients and synaptic transmission. However, unlike stronger carbonic anhydrase inhibitors, this effect is moderate and associated with fewer side effects.

The combined effect of sodium and calcium channel modulation along with carbonic anhydrase inhibition results in decreased excitatory neurotransmission and enhanced stabilization of neuronal membranes. Clinical studies demonstrate that this multimodal action is beneficial as adjunctive therapy for medically refractory partial seizures, often producing additive or synergistic effects with other anticonvulsants. Compared to other anticonvulsants, zonisamide’s broad mechanism provides efficacy in diverse seizure types with a relatively favorable side effect profile.

Pharmacological Actions

Voltage-gated sodium channel blockade leading to stabilization of neuronal membranes.
Inhibition of T-type calcium channels reducing neuronal burst firing.
Mild inhibition of carbonic anhydrase resulting in altered cerebral ionic balance.
Reduction of neuronal hyperexcitability contributing to anticonvulsant effects.
Modulation of neurotransmitter release indirectly through ion channel effects.
Adjunctive anticonvulsant activity in partial-onset seizures.
Long half-life supporting once or twice daily dosing.
Minimal protein binding reducing displacement interactions.
Primarily hepatic metabolism via CYP3A4 with renal elimination of metabolites.
Moderate brain penetration achieving therapeutic CNS concentrations.

Therapeutic Or Clinical Uses

Adjunctive treatment of partial (focal) seizures in adults and adolescents aged 16 and older.
Management of medically refractory epilepsy requiring combination therapy.
Used when patients are intolerant or unresponsive to first-line anticonvulsants.
Potential off-label use in other seizure types, although not extensively studied.
Considered in patients needing once or twice daily dosing for seizure control.
Alternative therapy in patients with sulfonamide allergy with caution.
Treatment option for patients requiring anticonvulsants with mild carbonic anhydrase inhibition.
Adjunctive therapy when other anticonvulsants are inadequate or contraindicated.
Supplemental therapy in seizure management to improve quality of life.
Used in neurological disorders characterized by abnormal neuronal excitability.

Side Or Adverse Effects

Drowsiness and somnolence leading to impaired alertness and coordination.
Dizziness and vertigo potentially affecting balance.
Cognitive impairment such as memory problems and difficulty concentrating.
Behavioral changes including agitation, irritability, and mood swings.
Loss of coordination and ataxia with impaired gait.
Loss of appetite leading to weight loss in some patients.
Serious hypersensitivity reactions including rash, Steven-Johnson syndrome, and toxic epidermal necrolysis.
Signs of blood dyscrasias including fever, chills, and sore throat suggestive of bone marrow suppression.
Metabolic acidosis manifested by confusion, vomiting, and irregular heartbeat.
Kidney stones presenting as flank pain, hematuria, and pain on urination.
Decreased sweating and hyperthermia, particularly in children and hot climates.
Potential for vision changes and permanent vision loss;
Suicidal ideation or worsening depression and anxiety symptoms.
Gastrointestinal disturbances including nausea and diarrhea.
Allergic reactions including angioedema and anaphylaxis in sulfa-sensitive individuals.

Precautions

Use with caution in patients allergic to sulfonamides due to risk of hypersensitivity reactions.
Monitor mood and behavior changes closely as zonisamide may increase suicidal thoughts or depression.
Regular laboratory monitoring including blood counts, metabolic panels, and renal function is recommended.
Avoid abrupt discontinuation to prevent rebound seizures; taper dosage gradually.
Ensure adequate hydration to reduce risk of nephrolithiasis (kidney stones).
Exercise caution in patients with impaired renal or hepatic function; dose adjustments may be necessary.
Monitor for signs of metabolic acidosis, especially in patients on ketogenic diets or with impaired acid-base balance.
Pregnancy use requires risk-benefit assessment; effective contraception is essential during treatment.
Caution advised in patients with bone disorders as carbonic anhydrase inhibition may affect bone mineral density.
Warn patients about potential impaired ability to perform hazardous tasks like driving until effects are known.
Avoid concomitant use of CNS depressants without medical guidance to minimize additive sedation.
Discontinue at first sign of severe skin rash or systemic hypersensitivity.
Educate patients and caregivers to report any new or worsening psychiatric symptoms or suicidal ideation.
Closely monitor temperature regulation in children during hot weather due to hypohidrosis risk.
Use caution when combined with other medications affecting cytochrome P450 enzymes.

Warnings

Risk of permanent vision loss; immediate medical evaluation is required if eye pain, redness, or visual changes occur.
Serious and potentially fatal skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis may occur.
Decreased sweating and hyperthermia can lead to heat stroke; patients should avoid excessively hot environments.
Potential for increased seizure frequency or severity if therapy is abruptly discontinued.
Suicidal thoughts and behaviors reported; patients require monitoring for behavioral changes.
Contraindicated in patients with known hypersensitivity to zonisamide or sulfonamides.
Use during pregnancy may cause harm to the fetus; effective contraception required.
Severe allergic reactions including anaphylaxis possible; discontinue drug if reactions appear.
Risk of metabolic acidosis necessitates monitoring serum bicarbonate levels during treatment.
Potential drug interactions may exacerbate side effects or reduce efficacy.
Use with caution in patients with psychiatric disorders due to behavioral side effects.
Potential for kidney stones demands attention to hydration status and urinary symptoms.
Avoid excessive alcohol consumption to prevent additive CNS depressive effects.
Monitor for blood dyscrasias, manifested as fever, sore throat, and fatigue.
Extended half-life requires careful dose adjustments to prevent accumulation.

Contraindication

Known hypersensitivity or allergy to zonisamide.
History of severe allergic reaction to sulfonamide drugs due to cross-reactivity.
Patients with previous Stevens-Johnson syndrome or toxic epidermal necrolysis related to zonisamide.
Metabolic acidosis or significant acid-base imbalance pre-existing conditions.
Severe hepatic impairment given metabolism reliance on liver enzymes.
Renal failure or severe renal impairment without appropriate dose adjustment.
Concomitant use with other carbonic anhydrase inhibitors that may exacerbate side effects.
Use during pregnancy unless benefits outweigh risks and under close medical supervision.
Patients with known intolerance leading to blood dyscrasias or bone marrow suppression.
Children under 16 years of age due to lack of established safety and efficacy data.

Drug Interactions

CYP3A4 inducers (e.g., carbamazepine, phenytoin) may decrease zonisamide plasma concentrations, reducing efficacy.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase zonisamide levels, increasing toxicity risk.
Other central nervous system depressants (e.g., benzodiazepines, opioids) may potentiate sedative effects.
Concurrent use with other carbonic anhydrase inhibitors may increase risk of metabolic acidosis and kidney stones.
Drugs affecting renal excretion may alter zonisamide elimination and plasma levels.
Potential interaction with drugs prolonging QT interval requiring caution and monitoring.
Use with diuretics may increase risk of metabolic acidosis and electrolyte disturbances.
Co-administration with medications that lower seizure threshold may reduce seizure control.
Interactions with anti-hypertensive agents may occur due to zonisamide’s mild diuretic effect.
Herbal supplements such as St. John's wort could induce CYP3A4, decreasing zonisamide efficacy.
Alcohol consumption can increase CNS depression and impair cognitive functions.
Concomitant use of valproic acid may alter zonisamide pharmacokinetics and increase adverse events.
May affect metabolism or efficacy of hormonal contraceptives, necessitating additional precautions.
Interaction with mood stabilizers or antidepressants may potentiate neuropsychiatric side effects.
Caution advised with other medications metabolized via liver enzymes to avoid unexpected plasma changes.

Preparations Of The Drug

Oral capsules available in 25 mg, 50 mg, and 100 mg strengths for flexible dosing.
Oral suspension preparation with concentration of 100 mg/5 mL suitable for patients requiring liquid formulation.
Capsules designed to be swallowed whole without crushing or chewing.
Oral suspension requires shaking prior to administration to ensure uniform dosing.
Supplied with measuring device for accurate dosing of suspension.
Packaging includes storage instructions to protect from moisture, heat, and light at room temperature.
Suspension should be discarded 30 days after opening to maintain potency and safety.
Available under brand names Zonegran and Zonisade with FDA approval for seizure adjunctive therapy.
Multiple generic formulations exist to improve accessibility and affordability.
Dosage forms formulated to provide consistent and predictable pharmacokinetic profiles.
Encapsulation technology ensures stability of drug substance and controlled release.
Formulations designed to minimize gastrointestinal irritation and improve patient adherence.
Manufactured according to stringent quality control to ensure purity and efficacy.
Patient information leaflets included to support safe use and understanding of therapy.